


**LISTING OF THE CLAIMS**

No amendments are presented.

1 (previously presented): N-phenyl-2-pyrimidine-amine derivative represented by the following formula (1):




and its salt, in which

R<sub>1</sub> represents 3-pyridyl or 4-pyridyl,

R<sub>2</sub> and R<sub>3</sub> each represent hydrogen or lower alkyl,

R<sub>6</sub> or R<sub>7</sub> represents a radical having the following formula (2):



wherein X represents oxygen or NH, n=0 or 1, and R<sub>9</sub> represents piperidine or 4-methylhomopiperazine when n=0, or 4-methylpiperazine when n=1, and


R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub> each represent hydrogen, or one or two thereof each represent halogen, lower alkyl, or lower alkoxy when R<sub>6</sub> represents the radical of the above formula (2), or R<sub>4</sub> represents hydrogen and one or two of R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> each represent halogen, lower alkyl or lower alkoxy, or R<sub>4</sub> represents methyl or methoxy, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> represent hydrogen, and R<sub>9</sub> represents lower alkyl-substituted homopiperazine, when R<sub>7</sub> represents the radical of the above formula (2), provided that R<sub>6</sub> or R<sub>7</sub> represents a radical of formula (2) wherein n=0 and R<sub>9</sub> is 4-methylpiperazine, then one or more of R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub>, or one or more of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> are halogen.

2 (previously presented): The compound of claim 1 wherein

R<sub>1</sub> represents 3-pyridyl,

R<sub>2</sub> and R<sub>3</sub> each represent hydrogen,

R<sub>6</sub> or R<sub>7</sub> represents a radical having the following formula (2):



wherein X represents oxygen or NH, n=0 or 1, and R<sub>9</sub> represents piperidine or 4-methylhomopiperazine when n=0, or 4-methylpiperazine when n=1, and

R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub> each represent hydrogen, or one or two thereof each represent fluoro, methyl, or methoxy when R<sub>6</sub> represents the radical of the above formula (2), or one or two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>8</sub> each represent fluoro, methyl, or methoxy when R<sub>7</sub> represents the radical of the above formula (2).

3 (original): The compound of claim 1 wherein R<sub>1</sub> represents 3-pyridyl, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>, and R<sub>8</sub> each represent hydrogen, and R<sub>6</sub> represents the radical of formula (2)

wherein n=0 and R<sub>9</sub> represents 4-methylhomopiperazine, or n=1, X represents NH, and R<sub>9</sub> represents 4-methylpiperazine.

4 (original): The compound of claim 1 wherein R<sub>1</sub> represents 3-pyridyl, R<sub>2</sub> and R<sub>3</sub> each represent hydrogen, R<sub>4</sub> represents methyl, R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> each represent hydrogen, and R<sub>7</sub> represents the radical of formula (2) wherein n=1, X represents NH, and R<sub>9</sub> represents 4-methylpiperazine.

5 (cancelled).

6 (original): A pharmaceutical composition for the treatment of lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, which comprises an effective amount of the compound

of formula (1) or its salt as defined in claim 1 as an active ingredient together with pharmaceutically acceptable inert carriers.

7 (original): The composition of claim 6 which is used as an oral preparation.

8 (original): The composition of claim 6 which is used as an injection.

9 (cancelled).